UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
We describe how low index readings can signal weakening momentum, possible capitulation, or upcoming reversals, with practical interpretation tips.
21,854 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Investors are asking if costco stock going $1,500? is possible. This guide breaks down what would have to happen, the...
Oil is rising and energy stocks are drawing cautious buyers. This guide shows two resilient oil producers you could b...
A former NCAA champion credits running with reversing a growing body-image crisis among teen girls and easing related...
New York’s upstart candidate Jack Schlossberg argues JFK would be alarmed by America’s global standing, while acknowl...
Ethereum sits at a pivotal juncture around $2,160, with on-chain activity signaling caution and institutional demand ...
A blue-chip dividend staple offers resilience in volatile markets. This guide explains why Coca-Cola stands out, how ...
EQT Corp is becoming a cash machine, with free cash flow rising and margins expanding. Wall Street is warming to the ...
Nine months after Jim Cramer touted Energy Transfer as a top dividend pick for retirees, the stock has delivered on i...
XRP sits around $1.40 as institutions quietly expand tokenized-asset settlements on public rails, even as on-chain ac...
Doximity is due to report Q4 results after the close, with analysts keyed to FY2027 guidance and margin trajectory as...
Ares Capital's dividend looks tempting to many income investors, but sustainability hinges on cash flow, loan quality...